Key facts
- This page summarizes Erin Parsons's Form 4 filing for KIORA PHARMACEUTICALS INC (KPRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 13 Jun 2024, 15:51.
Erin Parsons - 13 Jun 2024 Form 4 Insider Report for KIORA PHARMACEUTICALS INC (KPRX)
- Reporting relationship
- Director
- Issuer ticker
- KPRX
- Reported as of
- 13 Jun 2024
- Net transaction value
- +$25,669
- SEC form
- 4
- Accepted by SEC
- 13 Jun 2024, 15:51:05 UTC
- Prior SEC filing
- 04 Oct 2023
- Next SEC filing
- 03 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Melissa Tosca, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Erin Parsons filed Form 4 for KIORA PHARMACEUTICALS INC (KPRX) on 13 Jun 2024.
Change
- Previous filing in this sequence was filed on 04 Oct 2023.
- Current net transaction value: +$25,669.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KPRX
transaction
Common Stock
Purchase
- Transaction value
- $25,669
- Shares
- +5,260
- Change %
- Price
- $4.88*
- Shares after
- 5,260
- Date
- 13 Jun 2024
- Ownership
- By spouse
* marks a reported price that did not pass the local price check.